Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 4,193,562	$ 5,277,335
General and administrative	1,660,534	2,096,954
Operating loss	(5,854,096)	(7,374,289)
Other income (expense), net:
Interest income (expense), net	168,055	(848)
Other income (expense), net		(401,964)
Net loss	$ (5,686,041)	$ (7,777,101)
Per common share data:
Basic net loss per common share	$ (0.17)	$ (0.23)
Diluted net loss per common share	$ (0.17)	$ (0.23)
Weighted average number of common shares outstanding, basic	33,966,921	33,504,472
Weighted average number of common shares outstanding, diluted	33,966,921	33,504,472
Other comprehensive income (loss):
Foreign currency translation gain (loss)	$ (81,335)	$ 522,771
Comprehensive loss	$ (5,767,376)	$ (7,254,330)